Adam S Myer, Drake A Seccurro, Kenneth E Sherman, Yeshika Sharma
{"title":"Outcomes following the use of HBsAg-positive liver allografts in HBsAg-negative recipients.","authors":"Adam S Myer, Drake A Seccurro, Kenneth E Sherman, Yeshika Sharma","doi":"10.1097/LVT.0000000000000533","DOIUrl":null,"url":null,"abstract":"<p><p>The use of positive HBsAg (HBsAg+) liver allografts has been increasing globally and is gaining wider acceptance within the United States. However, most of the data supporting the use of HBsAg+ organs has been in the setting of recipients with chronic hepatitis B. We aim to describe our institutional experience using HBsAg+ liver donors in HBsAg-negative recipients through case series. Between 2019 and 2021, 10 HBsAg-negative recipients received an HBsAg+ liver transplant. Kaplan-Meier survival analysis showed no difference in survival when compared to all other liver transplants performed at the institution during the same period ( p = 0.5, HR = 1.6, CI = 0.4-6.5). Based on these findings, the use of HBsAg+ liver donors appears to be safe; however, continued follow-up is required to understand further risks associated with the use of HBsAg+ liver allografts.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":" ","pages":"870-876"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/LVT.0000000000000533","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The use of positive HBsAg (HBsAg+) liver allografts has been increasing globally and is gaining wider acceptance within the United States. However, most of the data supporting the use of HBsAg+ organs has been in the setting of recipients with chronic hepatitis B. We aim to describe our institutional experience using HBsAg+ liver donors in HBsAg-negative recipients through case series. Between 2019 and 2021, 10 HBsAg-negative recipients received an HBsAg+ liver transplant. Kaplan-Meier survival analysis showed no difference in survival when compared to all other liver transplants performed at the institution during the same period ( p = 0.5, HR = 1.6, CI = 0.4-6.5). Based on these findings, the use of HBsAg+ liver donors appears to be safe; however, continued follow-up is required to understand further risks associated with the use of HBsAg+ liver allografts.
期刊介绍：
Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AASLD, Liver Transplantation delivers current, peer-reviewed articles on liver transplantation, liver surgery, and chronic liver disease — the information necessary to keep abreast of this evolving specialty.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
